Real‐world study of the use of azacitidine in myelodysplasia in Australia

Abstract Hypomethylating agents are the most widely used upfront therapy for patients with myelodysplastic syndrome (MDS) who are not suitable for hematopoietic stem cell transplantation. In Australia, azacitidine was, until recently, the only approved and subsidized treatment for patients with inte...

Cijeli opis

Bibliografski detalji

Glavni autori:	Anoop Enjeti, Asma Ashraf, Vincent Caillet, Arif Alam, Jonathan Silar, Harold Keer, Francesco Castaldi, Taleisha Paine
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2024-06-01
Serija:	eJHaem
Teme:	azacitidine hypomethylating agents myelodysplastic syndromes real‐world survival
Online pristup:	https://doi.org/10.1002/jha2.911
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!